Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Adhezion Biomedical, a developer of adhesive and anti-microbial sealant products for medical applications, has raised $2.1 million in second tranche of $5.25 million series A round.
Subscribe to our email newsletter
Adhezion said that its proprietary formulation can be used in a variety of applications including as an anti-microbial surgical sealant that creates a protective barrier to prevent infection, or to bond skin tissue, replacing sutures, staples and bandages.
According to the company, the products require no refrigeration or blending, dry faster, and are very flexible. They are sold under the SurgiSeal, FloraSeal and DermaSeal brands, targeted to surgeons and physicians.
Pete Molinaro, CEO of Adhezion Biomedicals, said: “This series A investment confirms the strength of our company and the efficacy of our approach. Our patented OctylFlex monomer process can be used in an extremely wide array of topical product applications, addressing skin lacerations, incisions and plastic surgery.
“It meets the needs of surgeons and patients seeking less disruptive, more natural healing solutions that are both durable and versatile.”